{"analyses":[{"groupDescription":"Esophagitis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4133","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Fisher Exact"},{"groupDescription":"Cardiac adverse events","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"1.000","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.5","upperLimit":"19.5","value":"7.1"},{"groupId":"OG001","lowerLimit":"0.8","upperLimit":"10.6","value":"3.8"}]}],"title":"Esophagitis"},{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"}]}],"title":"Pericardial Effusion"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"12.6","value":"2.4"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"6.8","value":"1.3"}]}],"title":"Cardiac adverse events"}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"description":"Common Terminology Criteria for Adverse Events (version 4.0) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; See Adverse Events Module for specific adverse event data.","dispersionType":"95% Confidence Interval","groups":[{"description":"60 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel.","id":"OG000","title":"Standard Radiation Therapy"},{"description":"A maximum of 80.4 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Radiation therapy dose is individualized for final 9 fractions based on imaging results from PET/CT scan between fractions 18 and 19.","id":"OG001","title":"Adaptive Radiation Therapy"}],"paramType":"NUMBER","populationDescription":"Eligible participants who started study treatment","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up: weekly during treatment, then 1, 3, 6, 9, 12, 18, 24, 30, 36, 48, and 60 months after end of protocol treatment, then annually. Maximum follow-up at time of reporting was 7.3 years.","title":"Percentage of Participants With Grade 3+ Esophagitis, Pericardial Effusion, and Any Cardiac Adverse Events at Any Time (NRG)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}